Is T-DXd Toxicity Worth the Tradeoff? Higher efficacy always raises the same question: what about toxicity?This conversation covers ILD risk, nausea management, radiation safety, and why patient-reported outcomes may matter just as much as survival curves. FacebookXRedditPinterestEmail You may also like Video Can T-DXd Change Early HER2+ Breast Cancer Forever? – Dr. Ruta Rao & Dr. VK Gadi 1 min read Video Why T-DXd Could Replace T-DM1 in High-Risk Patients 1 min read Video Early-Stage HER2+: Defining “High Risk” in Residual Disease 1 min read Video Neoadjuvant T-DXd: Why DESTINY-Breast11 Data Turned Heads 1 min read Video Does T-DXd + P Beat the CLEOPATRA Standard in First-Line Metastatic Disease? 1 min read Video Who Should NOT Get T-DXd Early? 1 min read Recommended Videos New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed 4 months ago Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich 4 months ago Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan 4 months ago Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea 4 months ago
New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed 4 months ago
Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich 4 months ago
Is T-DXd Rewriting First-Line HER2+ Metastatic Breast Cancer? – Dr. Mark Pegram & Dr. Fengting Yan 4 months ago
Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea 4 months ago